New and Emerging Therapies for Follicular Lymphoma, Including Treatment Challenges

A roundtable discussion, moderated by Kami J. Maddocks, MD, of the James Cancer Hospital, Ohio State University Comprehensive Cancer Center, focused on treatment options for diffuse large B-cell lymphoma and follicular lymphoma (FL), including novel emerging therapies and treatment sequencing considerations. Dr. Maddocks was joined by a panel that included Pierluigi Porcu, MD; Pamela Blair Allen, MD, MSc; and Jonathan W. Friedberg, MD.
In the next segment, the panel discusses novel treatment options for FL, including bispecifics, CAR-Ts, monoclonal antibodies, and more.
*Editor’s note: After the live taping of this roundtable, the FDA approved mosunetuzumab on December 22, 2022, for the treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.